HORIZON DISCOVERY BIOSCIENCES LIMITED

Horizon Discovery Biosciences Limited specializes in the design, development, and delivery of high-precision functional genomics tools for biomedical research and therapeutic target validation. The contractor produces synthetic RNA-based libraries—including siRNA and lentiviral shRNA pooled libraries—that enable large-scale gene knockdown studies across human cell lines. Their core expertise lies in genome-scale screening platforms, particularly those targeting the druggable genome, with applications in oncology, immunology, and precision medicine. Key differentiators include proprietary vector systems, high-fidelity library design, and the integration of standardized plate map metadata for reproducible experimental workflows. These capabilities support advanced phenotypic screening, CRISPR validation, and target identification in preclinical drug discovery pipelines. The contractor has delivered critical genomic tools to the Department of Health and Human Services and the Department of Defense, primarily supporting research initiatives in functional genomics and therapeutic development. For HHS, work focuses on enabling academic and institutional laboratories with scalable RNA interference libraries for gene function analysis. The DoD engagement centers on experimental systems evaluation using genome-wide siRNA libraries, indicating alignment with military biomedical research priorities such as infectious disease and trauma response. Horizon Discovery operates primarily under NAICS 325414, which encompasses the manufacturing of biological products excluding diagnostics. In practice, this translates to the industrial-scale production of engineered nucleic acid reagents for life science research. The company is positioned as a niche supplier of high-complexity, research-grade genomic tools rather than clinical-grade biologics, serving the preclinical R&D segment of the biopharmaceutical and government-funded science markets. As a UK-based entity structured as a 2L corporation, Horizon Discovery operates without U.S. government certifications but maintains a focused presence in the federal research procurement landscape through direct delivery of specialized biological reagents. Their geographic footprint is centered in Cambridge, UK, with supply chains calibrated to meet the regulatory and logistical demands of U.S. federal research institutions.